Special Drug Use-results Survey for Long-term Administration of Invega 3mg/6mg/9mg Tablet

Special Drug Use-results Survey for Long-term Administration of Invega 3mg/6mg/9mg Tablet - Special Drug Use-results Survey for Long-term Administration of Invega 3mg/6mg/9mg Tablet

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015599

Enrollment

1350

Registered

2014-11-07

Start date

2011-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with schizophrenia who are treated with Invega Tablet for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Sefety(Adverse Drug Reaction) Effectiveness(Clinical Global Impression-Schizophrenia)	—

Secondary

Measure	Time frame
Effectiveness(Social and Occupational Functioning Assessment Scale)	—

Countries

Japan

Contacts

Public ContactKeiko Imai

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

kimai4@ITS.JNJ.com03-4411-5752

Outcome results